Retroperitoneal fibrosis in a patient with macroprolactinoma treated with bromocriptine.

Abstract

8RF) write: Many reports document a variety of neurological complications resulting from both intravenous and intrathecal administration of methotrexate, but acute cerebral oedema is not among them. We describe a patient with acute myeloid leukaemia who developed cerebral oedema after treatment with intrathecal methotrexate. A 23 year old Jamaican woman was admitted with a diagnosis of acute pnyeloid leukaemia (M3).

Treatment of Parkinson's Disease with Ropinirole after Pergolide‐Induced Retroperitoneal Fibrosis

“…However, earlier therapy with bromocriptine is a confounding variable, as bromocriptine has been associated with RPF. [4][5][6][7][8] The time course from starting bromocriptine to clinically evident RPF in reported cases ranged from 1-10 years, but all patients were receiving the drug at the time of diagnosis. There may be some dose dependency with a dosage of 30-140 mg/day.…”

“…1 The association of ergot derivatives, including pergolide, with retroperitoneal fibrosis (RPF) is well documented. [2][3][4][5][6][7][8][9][10][11][12][13][14][15] Newer nonergot dopaminergic agonists (pramipexole, ropinirole) have the potential to be used without risk of RPF. 1…”

Deep Vein Thrombosis /Pulmonary Embolism in a Patient with Retroperitoneal Fibrosis: A Case Report

“…Beta-blockers, including metoprolol and eye drops containing timolol have been reported to associate with RPF [5] others include Ergot derivatives [6], hydralazine [7], bromocriptine [8] and methyldopa [9], pergolide [10]. Certain malignancies like lymphomas, gastric and pancreatic cancers have been found to be associated with RPF [11].…”

Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson’s disease

“…Drug‐related RPF is well recognized and in particular may be associated with the ergot derivatives methysergide [ 1] and bromocriptine [ 2]. Pergolide is an ergot‐derivative dopamine receptor agonist used in the treatment of Parkinson’s disease and there is one previous report suggesting an association with RPF [ 3].…”